TORONTO, ONTARIO--(Marketwire - June 30, 2010) - ISee3D Inc. (TSX VENTURE:ICT) announced today that it has entered into a license agreement with Hamilton Thorne Ltd., a leading provider of advanced laser systems and instruments for in-vitro cell applications.
Hamilton Thorne will combine commercial microscopes with their advanced laser imaging systems, utilizing ISee3D's patented single-lens single camera 3D technology, for stem cell regenerative medicine and fertility clinic markets worldwide. ISee3D and Hamilton Thorne are collaborating on prototype development with one of the world's leading lens and microscope designers and manufacturers, with the objective of having a commercial product ready for sale in 2011.
"This agreement with Hamilton Thorne lays out a clear commercialization path for microscopes empowered with our single-lens single camera 3D technology," said ISee3D CEO Dwight Romanica. "We look forward to working with Hamilton Thorne, and our design and manufacturing partner, on development of both a prototype and a leading commercially ready single-lens single camera 3D microscope."
"Our research customers have long sought a simple and cost effective method to incorporate true 3D images into their laser applications," says Meg Spencer, Hamilton Thorne CEO. "I believe that the extraordinary quality of the image in the ISee3D technology will represent a major advantage to researchers in the IVF and stem cell fields."
Under the terms of the agreement, ISee3D has granted Hamilton Thorne exclusive worldwide rights, for a three-year period, to commercialize a product, incorporating ISee3D's single-lens 3D technology in their laser imaging systems used in stem cell regenerative medicine and fertility clinic markets worldwide. Hamilton Thorne has agreed to pay ISee3D a one-time license fee of $150,000.00 USD, in addition to a royalty on each unit sold. Under the agreement, ISee3D is also guaranteed a minimum annual royalty.
About ISee3D Inc.
ISee3D Inc. (TSX VENTURE:ICT) owns certain patented technology which provides for the capture of stereoscopic (3D) images through a single lens. The Company's technology has broad applications in a variety of markets including the home entertainment industry, and consumer electronics, as well as industrial and imaging devices of all types including microscopes, endoscopes as well as more sophisticated medical imaging systems.
Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.